The expanded approval was based on safety and efficacy data from a confirmatory Phase 3 randomized, double-blind, placebo-controlled multicenter study evaluating Osphena in patients with moderate to severe vaginal dryness.
Higher mindfulness and lower stress are independently associated with lower menopausal symptom scores among midlife women.
Initiation and continuation trends in menopausal hormone therapy may have been influenced by the premature cessation of the 2002 Women’s Health Initiative trial, which was halted due to safety concerns.
A study was conducted to assess the safety, tolerability, and efficacy of methyl estradiolpropanoate, a topical soft estrogen cosmeceutical for the treatment of estrogen-deficient skin.
Oral preparations of hormone replacement therapy for the treatment of menopausal symptoms are associated with a greater risk for VTE compared with transdermal formulations.
Vaginal estrogen use or nonuse did not carry different risks for cardiovascular outcomes, cancer outcomes, or hip fracture.
Postmenopausal women with edentulism are at an increased risk for developing hypertension.
Intimate partner violence, sexual assault, and symptoms of posttraumatic stress disorder may be associated with menopause symptoms.
Fetal exposure to famine is associated with an increased risk for early menopause.
Oxybutynin, an anticholinergic used to treat urinary incontinence, may provide breast cancer survivors with an alternative treatment option for hot flashes, according to new research.
To investigate the association between hormone therapy and carpal tunnel syndrome risk, researchers conducted a secondary analysis of the Women’s Health Initiative (WHI) hormone therapy trials.